Technology
eClinical Solutions Market to Grow by USD 12.77 Billion (2024-2028), Rising Drug Clinical Trials Drive Revenue, Report Highlights AI Impact on Trends – Technavio
Published
2 years agoon
By
NEW YORK, Dec. 5, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global eclinical solutions market size is estimated to grow by USD 12.77 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 15.26% during the forecast period. Rise in clinical trials for drugs is driving market growth, with a trend towards increasing outsourcing of clinical trial processes. However, rising cost of clinical trials poses a challenge. Key market players include Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC.
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF
Forecast period
2024-2028
Base Year
2023
Historic Data
2018 – 2022
Segment Covered
End-user (Pharmaceutical and biotechnology companies, Contract research organizations, Consulting service companies, Medical device manufacturers, and Others), Deployment (Cloud-based and On-premises), and Geography (North America, Europe, Asia, and Rest of World (ROW))
Region Covered
North America, Europe, Asia, and Rest of World (ROW)
Key companies profiled
Advarra Inc., Aixial, Anju Software Inc., ArisGlobal LLC, Castor Research Inc., Dassault Systemes SE, DATATRAK International Inc., eClinical Solutions LLC., eClinicalWorks LLC, eResearchTechnology GmbH, International Business Machines Corp., MedNet, Medrio Inc., OpenClinica LLC, Oracle Corp., Parexel International Corp., Saama Technologies Inc., Signant Health, Veeva Systems Inc., and YPrime LLC
Key Market Trends Fueling Growth
The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for various chronic diseases such as cancer, cardiovascular conditions, and infectious diseases. The enormous data generated during these trials requires advanced software solutions for clinical data management (CDM) and clinical trial management systems (CTMS). EClinical solutions like Veeva Systems and PAREXE are gaining popularity due to their benefits of real-time access, error reduction, and cost efficiency. The rising number of clinical trials and observational studies, coupled with research funding, is driving the adoption of eClinical solutions. However, the lack of awareness and high costs are challenges for smaller enterprises and underdeveloped markets. The digitization of healthcare through the Internet of Things and information technologies is also influencing the market. Firms like TRIO and CROs are focusing on clinical randomization, supply management, and site performance to improve drug development and retention. Healthcare engineering, clinical researchers, and healthcare providers are also integrating eClinical solutions into their clinical trial processes, leading to growth opportunities for eClinical solution providers. The market is characterized by a firm concentration ratio, with major players like Veeva Systems and PAREXE dominating. The market also includes academic universities, hospitals, research centers, and process outsourcing firms. The development of medical devices and IT infrastructure, such as EDC, CDMS, and web-hosted or cloud-based clinical trials, are also contributing to the market’s growth. Consultancy services and licenced enterprise solutions are also available to support the market.
The eClinical Solutions Market has witnessed significant changes in the past decade, with a shift towards outsourcing drug discovery processes to subcontract laboratories. This trend is driven by increased R&D investments and the focus on core competencies in manufacturing and marketing. Since 2011, the number of subcontract laboratories has grown rapidly, and this trend is expected to continue. The industry has transformed from a vertical reporting model with in-house clinical study teams to a matrix model involving both external and internal resources. Gradually, the bulk of the work has moved to Contract Research Organizations (CROs). This outsourcing trend enables companies to reduce costs, improve efficiency, and focus on their core competencies.
Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!
• The eClinical solutions market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development for unmet medical needs in healthcare. The rising number of clinical trials for chronic diseases such as cancer, cardiovascular conditions, and infectious diseases, requires enormous data management. EClinical solutions like Veeva Systems and TRIO are addressing these challenges by providing software solutions for clinical data management (CDM), clinical trial management systems (CTMS), and clinical randomization. However, there are challenges such as high costs, lack of awareness, and integration issues with various systems like CDM, clinical research organizations (CROs), academic universities, hospitals, and research centers. The digitization of healthcare through the Internet of Things and information technologies is driving the need for data standardization and real-time access to clinical trial data. Smaller enterprises and developing markets face challenges in technology adoption due to the high costs and lack of internet connectivity. However, the benefits of eClinical solutions like cost efficiency, site performance, and error reduction make them an attractive option for clinical researchers and healthcare providers. Firms with a high firm concentration ratio, such as pharmaceutical companies and medical device manufacturers, are investing in eClinical solutions for clinical trial processes, supply management, and protocol matrices. Consultancy services like PAREXE are providing expertise in clinical trial processes and regulatory compliance to help firms navigate the complex clinical trial landscape. The growth opportunities in this market are vast, with a particular focus on clinical trial processes, drug development, and clinical research.
• Clinical trials are a crucial part of bringing new drugs to market, but their cost has become a significant concern. Factors contributing to this increase include the complex and lengthy process of patient enrolment and retention. According to recent studies, the cost per patient in clinical trials rose by over 150% in the US between 2010 and 2015, and by 85-90% in the UK during the same period. These figures underscore the need for effective clinical trial management solutions to streamline processes, improve patient engagement, and reduce costs.
Insights into how AI is reshaping industries and driving growth- Download a Sample Report
This eclinical solutions market report extensively covers market segmentation by
End-user 1.1 Pharmaceutical and biotechnology companies1.2 Contract research organizations1.3 Consulting service companies1.4 Medical device manufacturers1.5 OthersDeployment 2.1 Cloud-based2.2 On-premisesGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)
1.1 Pharmaceutical and biotechnology companies- Clinical trials are a crucial part of the drug development process for pharmaceutical and biotechnology companies. The success of these trials is essential for bringing new treatments to market. However, clinical trials are lengthy and expensive, and failures can result in significant financial and time losses. Regulatory scrutiny and the need for high-quality data have led to the increased adoption of eClinical solutions, such as Clinical Trial Management Systems (CTMS), among these companies. Mundipharma Research, a pharmaceutical research and development company, and GlaxoSmithKline, one of the largest pharmaceutical companies, are among those that have implemented eClinical solutions to enhance the efficiency and control of their clinical trials. These web-based systems provide real-time access to trial information, faster decision-making, decreased trial costs, and increased employee productivity and job satisfaction. With the rise in the number of clinical trials due to the increasing number of diseases and advanced treatments in development, the demand for eClinical solutions is on the rise. These solutions help companies manage the complexities of clinical trials, ensuring regulatory compliance, data accuracy, and operational efficiency. The market for eClinical solutions is expected to grow significantly during the forecast period as more companies recognize the benefits of these technologies in bringing new treatments to market.
Download complimentary Sample Report to gain insights into AI’s impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 – 2022)
The eClinical solutions market is experiencing significant growth due to the enormous data generated from clinical trials in healthcare. The rising number of clinical trials and emphasis on eClinical solutions for research is driving the market forward. Software solutions like ClinicalTrials.gov and TRIO are increasingly being adopted by cancer centers and healthcare institutions to streamline clinical research. Observational studies are also benefiting from eClinical solutions, allowing for more efficient data collection and analysis. The Internet of Things (IoT) is playing a major role in the technology adoption, enabling real-time patient monitoring and data collection. Research funding agencies are recognizing the value of eClinical solutions and are encouraging their use in clinical research. Minor trials are also benefiting from these solutions, making clinical research more accessible and efficient for all.
The eClinical Solutions Market is experiencing significant growth due to the increasing emphasis on clinical trials and vaccine development in healthcare. With an enormous amount of data being generated in clinical research, there is a rising need for software solutions to manage this data effectively. EClinical solutions, such as TRIO and PAREXE, are gaining popularity in cancer centers, clinical research organizations (CROs), pharmaceutical companies, and academic universities. The digitization of healthcare and the Internet of Things are driving the adoption of eClinical solutions, which offer benefits like real-time access to clinical trial data, improved clinical trial processes, and increased cost efficiency. However, the lack of awareness and high costs associated with these solutions pose challenges for smaller enterprises and underdeveloped markets. The market is characterized by a firm concentration ratio, with major players like Veeva Systems dominating. Growth opportunities exist in developing and underdeveloped markets, where there is a high demand for clinical trials in chronic diseases such as diabetes, cancer, cardiovascular conditions, and infectious diseases. EClinical solutions include Clinical Trial Management Systems (CTMS), Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), and Clinical Randomization Systems. These solutions help manage clinical trial processes, supply management, site performance, and retention. The benefits of eClinical solutions include error reduction, data standardization, and improved communication between clinical researchers, healthcare providers, and academic universities. However, the adoption of these solutions requires IT infrastructure and internet connectivity, which can be a challenge in some markets. Medical devices and consultancy services are also integral to the eClinical Solutions Market, offering additional benefits like protocol matrices, drug development, and clinical research. Overall, the market is expected to continue growing as unmet medical needs and the importance of clinical trials in drug development increase.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
End-userPharmaceutical And Biotechnology CompaniesContract Research OrganizationsConsulting Service CompaniesMedical Device ManufacturersOthersDeploymentCloud-basedOn-premisesGeographyNorth AmericaEuropeAsiaRest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/eclinical-solutions-market-to-grow-by-usd-12-77-billion-2024-2028-rising-drug-clinical-trials-drive-revenue-report-highlights-ai-impact-on-trends—technavio-302322403.html
SOURCE Technavio
You may like
Technology
Unity: The Convergence of the Three Main Red Army Forces
Published
40 minutes agoon
October 21, 2026By
BEIJING, Oct. 21, 2026 /PRNewswire/ — An interview from China.org.cn with Wang Xiaohui and David Ferguson on the Long March:
Wang Xiaohui:
We have all been through something similar — a group of people disagreeing with one another, with each side holding sound reasons to believe their own judgment is correct.
In such moments, should they part ways, or find another path forward together?
David Ferguson:
The word “unity” is often understood as a strategy. People unite when they face a common enemy, and when that enemy disappears, the cooperation ends with it. But I’ve always wondered if there is a different kind of unity — one not forged by a common enemy, but by a common destination. A unity that isn’t temporary, that doesn’t fall apart the moment circumstances change. I wanted to find out.
Wang Xiaohui:
An arduous expedition like the Long March posed unparalleled trials for any military unit.
Bitter cold on snow-capped mountains, hidden mire across marshlands, and dangers lurking every step of the way; food and warm clothes were constantly scarce, while enemies and artillery fire were relentless. Even so, through the Long March, these poorly equipped and raggedly dressed Red Army troops remained tightly bonded as one.
This bond was not coerced by harsh military discipline, but arose spontaneously from every soldier’s heart. Before they even set off, shared ideals and conviction had already taken deep root within every soldier, steeling their resolve to follow the Communist Party of China without hesitation. Along the trail, officers and soldiers of the Red Army ate from the same pots and wore uniforms made from the same coarse cloth. High-ranking commanders like Zhu De and Peng Dehuai covered most of the journey on foot alongside their troops, leaving their horses to the ill and wounded, while splitting their last rations with soldiers. Amid food shortages, even when columns in the front discovered edible greens, they would never dig them all up; instead, they sent words to rear units so that all troops could share.
The Red Army’s unity took root in shared ideals, flourished under equal treatment for all, and was forged through countless moments of entrusting each other with their lives. It also became the unshakable foundation that carried them through every ordeal.
In the late autumn of 1936, the Loess Plateau in northwestern China witnessed two hopeful rendezvous, marking the Long March’s triumphant close. First in Huining, soldiers of the First and Fourth Front Armies embraced in a long-awaited reunion. Just over 10 days later, at Jiangtaibu, the waiting First Front Army finally greeted the travel-worn soldiers of the Second Front Army.
Many of these soldiers had never met before, yet they greeted one another like long-lost brothers, eyes brimming with tears as they clasped hands. Officers and soldiers of the First Front Army sent whatever supplies they had saved up to their brother troops. Three battle-hardened columns merged into a mighty iron stream across the plateau. Just one month later, they fought in coordinated formation to secure triumph in the battle of Shanchengbao, putting a glorious full stop to the Long March.
When scattered sparks merge, inherent unity surges into a mighty force, powerful enough to rewrite an army’s fate and shift the course of a nation’s history.
At the time, Japanese invaders advanced deeper into China, occupying more and more territory, yet the civil war persisted. The CPC clearly understood that brutal conflict among the Chinese would only play to the invaders’ hands, and only national unity could safeguard the motherland. The CPC publicly called for an end to the civil war and joint resistance against Japanese invaders, officially proposed to build the national united front against Japanese aggression, and even took the initiative to halt military operations and withdraw troops as a gesture of goodwill — when the survival of a nation hung by a thread, they chose to unite all Chinese people.
The two KMT officers, Zhang Xueliang and Yang Hucheng, who were stationed in the northwest, witnessed the nation’s peril and were touched by the CPC’s advocacy of a united resistance. Resolved to collaborate with the CPC to fend off Japanese aggression, Zhang and Yang repeatedly pleaded with Chiang Kai-shek to shift focus to national defense, but to no avail. Ultimately, they detained Chiang by force, which later became known as the Xi’an Incident.
When word spread of Chiang’s detention, many assumed the CPC would demand a public trial, given years of bitter partisan strife. Instead, Zhou Enlai personally traveled to Xi’an with the CPC delegation to mediate, laying out the stakes for all parties concerned: executing Chiang would only result in a much larger-scale civil war, handing the Japanese aggressors golden opportunities to advance further into China. The only path to a promising future for the Chinese nation lay in a peaceful settlement that would compel Chiang to join the resistance against Japanese aggression.
Setting aside partisan divisions and prioritizing the supreme interests of the nation — this was the answer delivered by the CPC. At last, the Xi’an Incident was settled in peace, bringing an end to a decade of war. Since then, the Chinese nation finally stood united in fighting back against foreign invasion.
Nearly a century has passed, yet the spirit of unity forged on the Long March has never faded.
In September 1949, the First Plenary Session of the Chinese People’s Political Consultative Conference (CPPCC) was convened, officially instituting the system of multiparty cooperation and political consultation under the leadership of the Communist Party of China. The spirit of solidarity tempered amid the Long March was thereafter embedded in the very fabric of China’s governance system, with unity becoming one of its enduring tenets.
From the early reconstruction years since the founding of the People’s Republic of China in 1949, through the era of reform and opening up since 1978, to today’s march toward China’s modernization, each successive trial has burnished this core spirit of unity. In the fight against absolute poverty, the whole nation pulled together as a single force: the more developed eastern regions lent robust support to underdeveloped western regions, officials devoted themselves to working at grassroots communities, and local residents worked hard and strove for self-improvement. Together, hundreds of millions of Chinese worked to eradicate absolute poverty nationwide. When earthquakes and floods struck, rescue teams rushed to disaster zones from every corner of the country, while relief supplies and charitable donations poured in ceaselessly.
From the helping hands extended between soldiers along the Long March to the nationwide solidarity repeatedly demonstrated today, the essence of unity has never changed. It was the key that carried the Red Army through seemingly impossible odds, and it endures as China’s bedrock strength that propels China forward to this day.
David Ferguson:
After hearing the stories of the reunion of the three main forces of the Red Army and the Xi’an Incident, I found my answer.
The Long March showed me that unity is a condition for survival — not in the sense of “I need you for now, so let’s work together.” Rather, it was “We believe in a common cause, so we must stand together.” That kind of unity does not dissolve when the danger is gone, because it is rooted not in fear, but in conviction.
Whether I look at stories of the Long March or at China’s development today, what strikes me is not simply unity itself. What gives unity its power is the shared ideal that enables people to stand together, and the common mission that at critical moments, enables them to rise above the interests of the individual, of groups, and even of political parties.
Wang Xiaohui:
From the arduous trails of the Long March to the contemporary journey of national rejuvenation, when a group of people or a whole nation stand united around common ideals, they will always arrive at the future they hoped for, no matter how lengthy and winding the road ahead is.
China Mosaic
http://www.china.org.cn/video/node_7230027.htm
Unity: The Convergence of the Three Main Red Army Forces
http://www.china.org.cn/2026-10/20/content_118741729.shtml
View original content to download multimedia:https://www.prnewswire.com/news-releases/unity-the-convergence-of-the-three-main-red-army-forces-302914999.html
SOURCE China.org.cn
Technology
KingClean Debuts at the 140th Canton Fair with One-Stop ODM Solutions for Global Brands
Published
41 minutes agoon
October 21, 2026By
GUANGZHOU, China, Oct. 21, 2026 /PRNewswire/ — KingClean, a global leader in home appliances and cleaning solutions, showcased its latest smart home product line at the 140th Canton Fair, which includes cleaning appliances, kitchen and coffee equipment, drinking equipment, personal care and air comfort products. During the exhibition, KingClean held in-depth discussions with global channel partners at Booths E30–36 and F13–19, Hall 2.2, Zone A.
KingClean showcased over 40 innovative products. The cleaning appliances exhibition area covers cordless stick vacuum cleaners with docking stations, upright 3-in-1 wet-and-dry vacuum cleaner with steam, spot cleaner with steam, cordless mattress cleaners and canister. The kitchen appliance exhibition area showcases products such as cooking robot, commercial blenders, and fully automatic coffee machines. The water & beverage solutions area presents desktop intelligent water purifiers with functions of water purification, sparkling water, ice making, and tea brewing. In addition, KingClean balances personal care with environmental comfort, showcasing water-ion turbofan hair dryers, desktop air purifiers, and smart air circulation fans.
The collaboration between high-performance cleaning equipment and intelligent base stations is the key direction of this exhibition. The exhibits include cordless vacuum cleaners equipped with high-power motors, dust‑cup or dust‑bag docking stations, charging and automatic cleaning functions, as well as floor cleaning vacuum cleaners that integrate functions of steam cleaning, automatic water refilling, and hot air drying. Multiple reference models intuitively demonstrate how the same technology platform can flexibly adapt to different power levels, structural schemes, and accessory configurations.
KingClean also showcased a series of home fully automatic coffee machines, smoothies and ice-making equipment, as well as desktop intelligent beverage purifiers that supported flexible combinations of sparkling water, ice water, tea brewing, and coffee related modules in the beverage area. These exhibits could be further customized based on the customer’s beverage menus, usage frequency, and after-sales mode.
“We connect globally through innovative products, focusing on smart solutions that improve life and strengthen our leadership in the smart home industry” said Nate Yang, Senior Marketing Director at KingClean Electric Co., Ltd.
About KingClean
KingClean was founded in 1994 and is headquartered in Suzhou, China. The company specializes in high-end smart home appliances and mechatronic products, with motor as our core technology.
For more information, visit http://www.kingclean.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/kingclean-debuts-at-the-140th-canton-fair-with-one-stop-odm-solutions-for-global-brands-302914851.html
SOURCE KingClean
Technology
Husqvarna Group: INTERIM REPORT JANUARY – SEPTEMBER 2026
Published
41 minutes agoon
October 21, 2026By
STOCKHOLM, Oct. 21, 2026 /PRNewswire/ —
Consistent strategy execution in a continued challenging market
Third quarter 2026
Net sales decreased organically by 5%.Net sales decreased by 2% to SEK 9,012m (9,204), and included a positive impact of 3% from changes in exchange rates.Operating income amounted to SEK -334m (141) and the operating margin was -3.7% (1.5).Items affecting comparability (IAC) amounted to SEK -88m. These were primarily related to the execution of cost-saving initiatives.Excluding IAC, operating income amounted to SEK -246m (140), and the operating margin was -2.7% (1.5).Earnings per share (EPS) after dilution amounted to SEK -0.70 (-0.02) and EPS excluding IAC and after dilution amounted to SEK -0.58 (-0.02).Free operating cash flow was SEK 2,422m (2,423).Net debt was SEK 9.4bn (9.9).
January – September 2026
Net sales decreased organically by 2%.Net sales decreased by 5% to SEK 37,356m (39,184), and included an impact of -3% from changes in exchange rates.Operating income amounted to SEK 2,977m (3,735) and the operating margin was 8.0% (9.5).Items affecting comparability (IAC) amounted to SEK -445m. These were primarily related to the execution of cost-saving initiatives.Excluding IAC, operating income amounted to SEK 3,421m (3,742), and the operating margin was 9.2% (9.5).IEEPA-related tariff refunds of SEK 240m were recognized in COGS during the second quarter.Earnings per share (EPS) after dilution amounted to SEK 3.14 (4.43) and EPS excluding IAC and after dilution amounted to SEK 3.74 (4.44).Free operating cash flow was SEK 4,891m (4,743).
CEO Comment
We are making solid progress on our strategic priorities. Our cost savings program remains on track, recent product launches are receiving encouraging customer feedback, and we are broadening our presence across sales channels. Although these measures have not yet fully offset current market headwinds, they reinforce our confidence in the Group’s long-term competitiveness and prospects.
Financial performance summary
Net sales were SEK 9,012m (9,204), representing an organic decline of 5% in the quarter, primarily driven by continued weakness in Europe. Organic sales in the Husqvarna Forest & Garden Division declined by 10%, sales in the Husqvarna Construction Division were unchanged, while the Gardena Division delivered solid organic growth of 8%. Performance in the Husqvarna Forest & Garden Division was significantly affected by the widespread drought across large parts of Europe and continued weak consumer demand in key markets, including Germany and France. In contrast, strong growth in the Gardena Division’s Watering business highlighted the resilience of our diversified portfolio, gaining market shares in key markets, and the Husqvarna Construction Division has continued good momentum in its aftermarket business. I am also encouraged by continued growth across all three divisions in North America.
Operating income excluding IAC was SEK -246m (140), corresponding to a margin of -2.7% (1.5). The result reflected lower volumes in the Husqvarna Forest & Garden Division, an unfavorable product mix, inventory reductions and cost increases on raw materials and logistics costs. Free operating cash flow was stable at SEK 2,422m (2,423), as lower operating income was offset by changes in working capital, primarily driven by reduced inventories. We further strengthened the balance sheet, reducing net debt to SEK 9.4bn (9.9).
Executing on cost savings while navigating cost headwinds
Our transformative cost savings program remains on track to deliver SEK 3bn in gross savings by the end of 2028. Year-to-date savings reached approximately SEK 935m, including around SEK 305m in the third quarter, driven mainly by sourcing activities and personnel reductions. However, lower volumes, inventory reductions and cost headwinds continue to weigh on profitability. We are responding with targeted price increases, supply chain actions and product cost optimization, which will partly offset these pressures, although near-term headwinds are expected to remain.
We are advancing our asset-light strategy through further outsourcing initiatives. We will transfer production of selected Husqvarna-branded battery handheld products from Europe to Asia, using both our own facilities and external partners to enhance efficiency and competitiveness.
In addition, the ongoing discontinuation of the stone diamond tool business in the Construction Division, the phase-out of our Brastad component factory in the Husqvarna Forest & Garden Division and relocation of selected activities within Gardena’s European manufacturing network are progressing according to plan.
Unlocking the next phase of robotics growth
Our robotic lawn mowing business faced a difficult quarter, with adverse weather, competitive headwinds, and elevated channel partner inventories in Europe constraining demand for Husqvarna- and Gardena-branded products. Although recent performance has fallen short of expectations, we remain the clear market leader and we are confident in our strategy and longer-term development.
The strategic review of the Powered Garden BPU in the Gardena Division is ongoing and we aim to provide an update in the beginning of next year. Our priorities in the Husqvarna Forest & Garden Residential Robotics BPU include expanding our retail footprint and product range across price points and channels, strengthening the robotics organization and development model.
During the quarter, the US became the largest market in terms of sales for our Professional Robotics BPU, driven mainly by continued growth in the golf segment. Upcoming product launches and broader US distribution are expected to further strengthen our competitive position next season. We are also encouraged to be the first robotics company to receive conditional approval from the Federal Communications Commission (FCC) for foreign-produced advanced robotic devices in the US market.
Building a stronger, more competitive Husqvarna Group
We are accelerating change across the Group to create a leaner, more agile and asset-light organization. By challenging established ways of working, simplifying operations and acting decisively, we are strengthening competitiveness and profitability in the longer-term. Significant work remains, but I am confident we are moving in the right direction.
When consumer sentiment recovers, particularly in Europe, we will be well positioned to capture growth and improve earnings.
Glen Instone, CEO
Webcast presentation and telephone conference
A webcast presentation of the Q3 report hosted by Glen Instone, CEO and Patrik Johnson, CFO will be held at 9:00 CEST on Oct 21, 2026.
To view the presentation, please use this link.
The dial-in to the telephone conference (to ask questions):
+46 (0) 8 505 100 31 (Sweden) or +44 203 059 58 63 (UK)
Contact
Emelie Alm, Vice President, Investor Relations
+46 70 514 64 14
Husqvarna AB (publ), P.O. Box 7454, SE-103 92 Stockholm
Hälsingegatan 49, +46 8 738 90 00, www.husqvarnagroup.com
Reg. Nr: 556000-5331
(NASDAQ STOCKHOLM: HUSQ-A) (NASDAQ STOCKHOLM: HUSQ-B)
This report contains insider information that Husqvarna AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 07:00 CEST on Oct 21, 2026.
Factors affecting forward-looking statements
This report contains some forward-looking statements. These statements are subject to risks and uncertainties that may give rise to major deviations in the result due to several aspects. These aspects include, among other things: consumer demand and market conditions in the geographical areas and lines of business in which Husqvarna operates, the effects of currency fluctuations, downward pressure on prices due to competition, success in developing new products, outcome of product responsibility litigation and progress in terms of reaching the goals set for productivity and efficient use of capital.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/husqvarna-group/r/interim-report-january—september-2026,c4412543
The following files are available for download:
https://mb.cision.com/Main/996/4412543/4328797.pdf
Interim report Q3 2026 Husqvarna Group
View original content:https://www.prnewswire.com/news-releases/husqvarna-group-interim-report-january–september-2026-302915009.html
SOURCE Husqvarna Group
Unity: The Convergence of the Three Main Red Army Forces
KingClean Debuts at the 140th Canton Fair with One-Stop ODM Solutions for Global Brands
Husqvarna Group: INTERIM REPORT JANUARY – SEPTEMBER 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoHighland and Bath Counties, Virginia Go Live on a Shared Caliber Hosted CAD Environment
-
Technology4 days agoJinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
-
Coin Market5 days agoBitcoin price steadies around $82K after Fed’s Warsh avoids rate-hike hints
-
Near Videos4 days agoWhat if you could build a skyscraper with one prompt?
-
Technology5 days ago
/R E P E A T — Media Advisory – Minister Hodgson to deliver remarks and participate in fireside chat/
-
Technology5 days agoFrost & Sullivan: Netradyne Receives the 2026 Global Commercial Vehicle Video Telematics Product Leadership Recognition for Excellence in AI-Driven Fleet Safety and Operational Intelligence
-
Technology5 days agoFIRST LOOK: NINTENDO’S FIRST-EVER STORE-WITHIN-A-STORE EXPERIENCE IN NORTH AMERICA ARRIVES IN TORONTO
-
Technology3 days agoBioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar
